English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA blood test that uses artificial intelligence (AI) to detect cancer-related genetic changes and protein biomarkers could help screen women for early signs of ovarian cancer, according to a study by researchers at the Johns Hopkins Kimmel Cancer Center in collaboration with several other institutions in the United States and Europe.
Tag: Ovarian Cancer
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer Research on Saturday, September 21, 2024 in Seattle Washington.
Ovarian Cancer: Silent Killer
Ovarian cancer is often called the “silent killer”. Most of the time it has no symptoms in its early stages. By the time symptoms appear, the cancer may have already spread. This is why regular screenings are so important. Eugene…
The Medical Minute: Genetics play big role in ovarian cancer
Doctors can help prevent ovarian cancer, but historically the cost of preventative surgery has been menopause. A Penn State Health expert discusses why it’s worth it, and how medical technology is catching up with this insidious disease.
Chris Evert’s Ovarian Cancer Diagnosis Highlights the Importance of Yearly Gynecologic Appointments
As the US Open Grand Slam tournament gets underway this week, American tennis legend and ESPN commentator, Chris Evert, is making a comeback of her own. She returns to the broadcasting booth after experiencing an ovarian cancer recurrence which forced…
UNM Cancer Center Opens Ovarian Cancer Clinical Trial Using HIPEC Surgery
The University of New Mexico Comprehensive Cancer Center has opened a clinical trial that applies hyperthermic intraperitoneal chemotherapy (HIPEC) — a proven surgical technique that is used in digestive system cancers — to ovarian cancer.
Engineered Exosome-based Drug Delivery System for Synergistic Cancer Therapy
The researchers developed an exosome-based drug delivery system which employed synergistic miRNA-based autophagy inhibition and 7-coumarin-based chemotherapy for ovarian cancer therapy.
Precision Oncology via Artificial Intelligence on Cancer Biopsies
An artificial intelligence method to detect biomarkers in tumor biopsies promises to cut weeks and thousands of dollars from cancer detection, extending the benefits of precision oncology to underserved and under-resourced patients.
MD Anderson Research Highlights for July 24, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Mercy Medical Center’s Dr. Dwight Im Leads 14th Annual Gynecologic Robotic Surgery Conference in Baltimore, Maryland
The National Institute of Robotic Surgery at Mercy Medical Center presents the 14th annual Robotic Surgery Conference, “IMSWAY: A Systematic Approach to Advanced Robotic Gynecologic Surgery,” Oct. 3-5. 2024 at The Four Seasons Hotel, 200 International Drive in downtown Baltimore, MD.
Landmark Study Shows Elevated Cancer Risk for Women with Endometriosis
Women with endometriosis are four times more likely to develop ovarian cancer, and those with more severe cases are at an even greater risk.
Physician-scientist awarded two grants to develop immune therapies for ovarian cancer
Dr. Sanaz Memarzadeh has received two grants totaling $4.1 million to develop advanced cell based immune therapies for high-grade serous ovarian cancers that have become resistant to conventional treatments.
Revolutionizing Ovarian Cancer Treatment With Adaptive PARP Inhibitor Therapy
A new study led by researchers at Moffitt Cancer Center introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients. Their work is featured as the cover article of the June 19 issue of Cell Systems.
From Bench to Bedside on Ovarian Cancer
May 22nd marked a significant milestone in the collaborative efforts to combat ovarian cancer as the “International Dialogue on Ovarian Cancer, from Bench to Bedside” congress was held, bridging the gap between primary research and clinical practice.
Plant virus treatment shows promise in fighting metastatic cancers in mice
An experimental treatment made from a plant virus is effective at protecting against a broad range of metastatic cancers in mice, shows a new study from the University of California San Diego.
Tip Sheet: Funding awarded to two ovarian cancer research projects, progress towards liquid biopsies for lung cancer — and cannabis and alcohol use in patients
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.
Predicting Ovarian Cancer Relapse
Using spatial analysis of tissue samples, Cedars-Sinai investigators have identified patterns that could predict whether patients with the most common type of ovarian cancer will experience early relapse after treatment.
Yale Cancer Center Experts, Scientists to Share Vision and Research at Leading Conference
The five-day session (April 5-10), themed as “Inspiring Science. Fueling Progress. Revolutionizing Care,” will include new findings from Yale Cancer Center researchers.
APOLLO researchers uncover new target for ovarian cancer treatment
Scientists have identified a new target in ovarian cancer that is particularly vulnerable to chemotherapy. The discovery will allow researchers to better predict how this cancer will behave, particularly the most common and lethal, high-grade serous ovarian cancer (HGSOC). Ovarian cancer is one of the leading causes of cancer deaths among women.
Johns Hopkins Researchers Develop Test That Could Identify Aggressive Ovarian Cancers Early
Researchers at the Johns Hopkins Kimmel Cancer Center and the Department of Gynecology and Obstetrics at the Johns Hopkins University School of Medicine have developed an algorithm to identify high-risk precancerous lesions on the fallopian tubes.
The Foundation for Women’s Cancer to Host Free Patient and Advocates Education Forum in San Diego
The Foundation for Women’s Cancer (FWC) is pleased to host a free Patient and Advocate Education Forum on Friday, March 15, 2024, 10 a.m. – 4:30 p.m. PT, in San Diego, CA, at the San Diego Convention Center. The organization welcomes all gynecologic cancer (cervical, endometrial/uterine, ovarian, vaginal, and vulvar) patients, advocates, family members, and providers.
Common chemotherapy drugs don’t work like doctors thought, with big implications for drug discovery
A new study from the University of Wisconsin–Madison suggests that chemotherapy may not be reaching its full potential, in part because researchers and doctors have long misunderstood how some of the most common cancer drugs actually ward off tumors.
Researchers identify ‘switch’ to activate cancer cell death
A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.
Using personalized medicine to target gynecological cancers
In this interview, Dr. Salani, who is also a professor of obstetrics and gynecology in the David Geffen School of Medicine at UCLA, talks about the latest research advances for these cancers and how women can help reduce their risk and help with the early detection of the five main types of gynecologic cancers: cervical, ovarian, uterine, vaginal and vulvar.
Arkansas Author Pens Book Detailing Her Survival From Cancer
Angie Choi, a 2015 graduate of UA Little Rock, has written a book detailing how she survived her battle with ovarian cancer using a combination of conventional and alternative medicine.
Major Ovarian Cancer Discovery; Findings Published in Cell
The Birrer Laboratory at the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute helped discover a proteogenomic signature in ovarian cancer that may improve the way the disease is treated around the world. The discovery, which identifies a 64-protein-gene signature that can predict primary treatment resistance in patients with high grade ovarian cancer, was published Aug. 3 in the journal Cell.
MD Anderson Research Highlights for August 2, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments include a novel biomarker that may predict the aggressiveness of pancreatic cancer precursors, insights into the structure and function of a breast and ovarian cancer susceptibility gene, a new approach to overcoming treatment resistance in ovarian cancer, distinguishing features of young-onset rectal cancer, a biomarker and potential target for metastatic lung cancer, machine learning models to better predict outcomes of patients with mantle cell lymphoma (MCL), and a promising therapy for patients with relapsed/refractory MCL.
CAR-T immune therapy attacks ovarian cancer in mice with a single dose
CAR-T immune therapies could be effective against solid tumors if the right targets are identified, a new study led by University of Illinois Urbana-Champaign researchers suggests. The researchers successfully deployed CAR-T in a mouse model of ovarian cancer, a type of aggressive, solid-tumor cancer that has eluded such therapies until now.
Hairdressers, beauticians, accountants may be at heightened risk of ovarian cancer
Hairdressers, beauticians, and accountants are among certain job roles that may be associated with a heightened risk of ovarian cancer, finds a case-control study published online in the journal Occupational & Environmental Medicine.
Pharmacologist: Cancer drug shortage is delaying lifesaving treatments
This year, an estimated 2 million Americans will be diagnosed with cancer. Now, a New York Institute of Technology pharmacology expert contends that these patients’ realities could grow increasingly harsher, as a monthslong shortage of chemotherapy drugs continues. Low supplies of…
MD Anderson Research Highlights for June 7, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
New subtypes identified in difficult-to-treat ovarian cancer – Potential for discovering new treatments
Every year, more than 40,000 women die of ovarian cancer in Europe. Ovarian cancer is a genetically very heterogeneous disease, which makes it exceptionally difficult to study and treat.
Risks of removing ovaries at benign hysterectomy may outweigh the benefits for women at low risk for ovarian cancer
An emulated target trial of more than 140,000 women in Denmark found that removing the ovaries at benign hysterectomy was associated with increased risk for cardiovascular disease in younger women and cancer in older women at low risk for ovarian cancer. These findings support current recommendations for preserving ovaries in premenopausal patients. The findings are published in Annals of Internal Medicine.
AACR: Penn Medicine Preclinical Study Identifies New Target for Recurrent Ovarian Cancer
Results from a preclinical study from Penn Medicine, presented at the AACR Annual Meeting 2023, verified a new target for drug-resistant ovarian cancer and provided data to support a treatment approach that is already making its way into clinical trials.
MD Anderson Research Highlights for March 29, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
TRIAL’S LONG-TERM FOLLOW-UP DATA SHOWS NO DIFFERENCE IN OVERALL SURVIVAL AMONG OVARIAN CANCER PATIENTS WHO DID AND DID NOT RECEIVE PARP INHIBITOR MAINTENANCE THERAPY
After resolving missing data burdens, the ENGOT-OV16/NOVA (NCT01847274) study data shows no difference in overall survival for platinum-sensitive recurrent ovarian cancer (PSROC) patients who received PARP inhibitor niraparib maintenance therapy (MT) and those who did not. Results from the trial were presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute.
GYNECOLOGIC CANCER PATIENTS REPORT TIME-RELATED BURDENS AND FINANCIAL TOXICITIES IMPACT QUALITY OF LIFE
Time-related and financial burdens are detrimental to gynecologic cancer patient and survivor quality of life (QOL), according to two research studies presented yesterday and today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
CLINICAL TRIAL PARTICIPATION ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN OVARIAN CANCER PATIENTS
Clinical trial participation was associated with improved overall survival (OS) compared to standard of care therapy among women with platinum-resistant epithelial ovarian cancer (EOC), according to a research study presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
STUDY FINDS INTRIGUING OUTCOMES IN OVARIAN CANCER PATIENTS TREATED WITH PARP INHIBITORS BEFORE SURGICAL INTERVENTION AND SUBSEQUENT CHEMOTHERAPY
Administering PARP inhibitor (PARPi) olaparib prior to surgical intervention and chemotherapy in ovarian cancer patients – a new approach – is feasible and resulted in favorable surgical options, managed adverse events, and positive health outcomes, according to results from the Neoadjuvant Olaparib Window (NOW) Trial presented today by Shannon Westin, MD et al. at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
Study: Spice May Improve Ovarian Cancer Treatment
New research makes the case for why curcumin could help enhance treatment for ovarian cancer.
The Foundation for Women’s Cancer to Host Patient and Advocates Education Forum at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in Tampa on March 24
The Foundation for Women’s Cancer will host a Patients and Advocates Education Forum and Luncheon on Friday, March 24, 2023 in Tampa, FL during the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
MD Anderson Research Highlights for March 8, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Risk of cancer remains high for women over 50 with genetic BRCA1 or BRCA2 mutation
Although genetic mutations in BRCA1 or BRCA2 are associated with a younger onset of breast and ovarian cancer, women with these genetic mutations continue to face a high risk of cancer incidence after age 50, even if they have not been previously diagnosed with cancer.
UC San Diego Health Expert Available to Talk about New Recommendation for Ovarian Cancer Prevention
The Ovarian Cancer Research Alliance is urging some women to remove their fallopian tubes to avoid ovarian cancer, even those at low risk. The research group recommends eligible women to have the removal performed if they are finished having children…
Mayo Clinic researchers link ovarian cancer to bacteria colonization in microbiome
A specific colonization of microbes in the reproductive tract is commonly found in women with ovarian cancer, according to a new study from Mayo Clinic’s Center for Individualized Medicine. The discovery, published in Scientific Reports, strengthens evidence that the bacterial component of the microbiome — a community of microorganisms that also consists of viruses, yeasts and fungi — is an important indicator for early detection, diagnosis and prognosis of ovarian cancer.
MD Anderson Research Highlights for January 11, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
MD Anderson Research Highlights for December 19, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a cell cycle checkpoint inhibitor with potential therapeutic effects in an ovarian cancer subtype, a telementoring program for French-speaking oncology providers in Africa, insights into the relationship between obesity and immunotherapy side effects, updates to the world’s largest cancer drug discovery knowledgebase, improvements to treatment response by blocking the EGFR pathway, and a novel noninvasive diagnostic test for immunotherapy-related kidney injury.
Machine learning model builds on imaging methods to better detect ovarian lesions
Research from Quing Zhu’s lab yields a novel method to use ultrasound to enhance machine learning’s ability to accurately diagnose – or rule out – ovarian cancer.
Researchers Receive $3.2 Million to Study Efficacy of Mind-body Practices in Improving Pain, Surgical Outcomes
Can mind-body practices such as gentle yoga or self-reflection benefit patients undergoing surgery? It’s a question that researchers at Wake Forest University School of Medicine are examining with the support of a five-year, $3.2 million grant from the National Cancer Institute (NCI).
New Study in JNCCN Presents Evidence for ‘Tough Conversations’ Around Racism in Access to Cancer Care
A study in JNCCN, led by researchers at Duke University School of Medicine, found that Non-Hispanic Black patients were less likely to receive guideline-appropriate treatment for ovarian cancer compared to Non-Hispanic White patients, even after adjusting for healthcare access issues.